Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of Continuous Cardiac Rhythm Monitoring and Standard Care in Post-MI Patients With Significant Scar and Reduced LVEF (PRAETORIAN-LUX)

10 novembre 2026 aggiornato da: Reinoud. E. Knops, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Prospective Randomized Comparison of Standard Care Versus Continuous Cardiac Rhythm Monitoring of Patients With Significant Myocardial Scar and Moderately Reduced Ejection Fraction After Myocardial Infarction

After myocardial infarction (MI), reduced LVEF (≤35%) is a known risk marker for sudden cardiac death (SCD), yet many SCD cases occur with LVEF >35% as myocardial scarring remains a strong arrhythmogenic substrate regardless of preserved function. Non-sustained ventricular tachycardias ((NS)VTs) predict malignant arrhythmias and highlight the importance of early detection.

The primary objective is to determine whether continuous cardiac rhythm monitoring after myocardial infarction improves the detection of cardiac arrhythmias that require medical intervention by conducting a prospective, multi-center, international, randomized trial.

Panoramica dello studio

Stato

Reclutamento

Descrizione dettagliata

After myocardial infarction (MI), reduced left ventricular ejection fraction (LVEF ≤35%) is a well-known risk factor for sudden cardiac death (SCD), but many SCD cases occur in patients with preserved or mildly reduced LVEF (>35%) due to the arrhythmogenic potential of myocardial scar tissue. Non-sustained ventricular tachycardia (NSVT) is an early marker of malignant arrhythmias, underscoring the value of continuous rhythm monitoring. This prospective, multicentre, randomized trial investigates whether continuous cardiac rhythm monitoring using an implantable loop recorder in post-MI patients with LVEF >35 ≤50% and proven myocardial scar improves detection of clinically relevant arrhythmias compared with standard care. Secondary aims include evaluating the incidence of NSVT/VT/VF, premature ventricular contraction (PVC) burden, and the prognostic value of biomarkers such as NT-proBNP, Lp(a), IL-6, and CRP, as well as assessing patient safety perception and the potential health benefits of early intervention.

Tipo di studio

Interventistico

Iscrizione (Stimato)

256

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Reinoud E Knops, Professor, MD, PhD
  • Numero di telefono: +31205666555
  • Email: r.e.knops@amc.nl

Backup dei contatti dello studio

Luoghi di studio

    • North Holland
      • Amsterdam, North Holland, Olanda, 1105
        • Reclutamento
        • Amsterdam Medical Center Amsterdam
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients ≥ 18 years of age with a recent (≤ 12 months) STEMI or NSTEMI according to the definition by current ESC/AHA guidelines

  • LVEF >35-≤50% measured > 48 hours after index STEMI or NSTEMI

    o In case a candidate has an LVEF <35% after a recent MI, the responsible physician can decide to treat the patient with GDMT first and reassess the LVEF after 3 months post-MI

  • Clinically relevant myocardial scar, identified by one of the following criteria:

    • Post-MI TTE: Akinetic or dyskinetic myocardial segments seen on two anatomically adjacent echocardiographic segments suggestive for ischemic scar
    • Post-MI ECG: Pathologic Q-waves of ≥0.04 seconds in duration and ≥25% of the R wave amplitude in at least two contiguous leads
    • Post-MI MRI: Late gadolinium enhancement (LGE) in a typical ischemic distribution pattern, characterized by subendocardial or transmural involvement in at least one myocardial segment corresponding to a coronary artery territory, and confirmed on two orthogonal imaging planes
    • Post-MI nuclear imaging: Severely reduced perfusion and absent of metabolic activity in two or more contiguous segments, with tracer uptake less than 50%

Exclusion Criteria:

  • Patients implanted with any CIED or with a guideline indication for a CIED
  • Indication for chronic renal dialysis
  • Patients with life expectancy shorter than 12 months due to any medical condition
  • NYHA Class IV
  • Participation in another trial that may interfere
  • Woman who are pregnant or breast feeding

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Selezione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Implantable Cardiac Monitor arm

Patients undergoing an ICM implant for continuous cardiac monitoring

Implantable cardiac monitor implantation for continuous monitoring

Nessun intervento: Control group

Control group with standard of care without ICM implant

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to first documented cardiac arrhythmia prompting medical intervention
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Composite endpoint defined as the first documented cardiac arrhythmia that prompts a clinical action, including a change in medication, a diagnostic or interventional procedure, or hospitalization. Each participant contributes only their first qualifying event, regardless of arrhythmia type or clinical action. The outcome will be reported as the cumulative incidence of this composite event, expressed as a percentage, and compared between the insertable cardiac monitor (ICM) and standard-care groups using time-to-event analysis.

Throughout the planned 36-month participant follow-up period.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with non-sustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented non-sustained ventricular tachycardia (NSVT), ventricular tachycardia (VT), or ventricular fibrillation (VF). A participant meets the endpoint upon documentation of any component and is counted once, even if multiple components or episodes occur. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from any cause
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants who die from any cause during follow-up, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from a cardiovascular cause
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants who die as a result of a cardiovascular complication, as defined in the protocol, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with a documented cardiac arrhythmia
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented cardiac arrhythmias as defined in the protocol. A participant is counted once upon documentation of any qualifying arrhythmia, regardless of the number or type of subsequent arrhythmias. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented bradycardia
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether bradycardia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented sinus node dysfunction
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented sinus node dysfunction. Each participant is counted once. Counts will be reported by study group and according to whether sinus node dysfunction prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrioventricular block
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrioventricular block, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether atrioventricular block prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrial fibrillation
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrial fibrillation meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether atrial fibrillation prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented supraventricular tachycardia other than atrial fibrillation
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented supraventricular tachycardia other than atrial fibrillation, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether the arrhythmia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented non-sustained ventricular tachycardia
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented non-sustained ventricular tachycardia (NSVT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether NSVT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular tachycardia
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular tachycardia (VT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular fibrillation
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular fibrillation (VF) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VF prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving invasive interventions for cardiac arrhythmias
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants receiving at least one invasive clinical intervention for a documented cardiac arrhythmia. Each participant is counted once, regardless of the number of invasive interventions received. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with supraventricular arrhythmias necessitating clinical intervention
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented supraventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with bradycardia necessitating clinical intervention
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with ventricular arrhythmias necessitating clinical intervention
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented ventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving an implantable cardioverter-defibrillator
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing implantable cardioverter-defibrillator (ICD) implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving a pacemaker
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing pacemaker implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving appropriate implantable cardioverter-defibrillator therapy
Lasso di tempo: From ICD implantation through the end of the planned 36-month participant follow-up period.

Number of participants receiving at least one appropriate implantable cardioverter-defibrillator (ICD) therapy after ICD implantation. Each participant is counted once, regardless of the number of appropriate therapies received.

From ICD implantation through the end of the planned 36-month participant follow-up period.
Number of participants with complications related to insertable cardiac monitor implantation
Lasso di tempo: From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.

Number of participants in the ICM group experiencing at least one complication related to ICM implantation, including implantation-site infection, hematoma, or device migration. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
Number of participants with suspected serious complications related to arrhythmia-directed clinical interventions
Lasso di tempo: Throughout the planned 36-month participant follow-up period.

Number of participants experiencing at least one suspected serious complication related to a clinical intervention performed for a detected cardiac arrhythmia. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

Throughout the planned 36-month participant follow-up period.
Number of participants meeting the composite health-risk endpoint
Lasso di tempo: Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.

Composite endpoint comprising an increase of at least one NYHA class, heart failure admission, cardiovascular death, percutaneous coronary intervention, myocardial infarction, cerebrovascular accident, coronary artery bypass grafting, or valve surgery. A participant meets the endpoint if any component occurs and is counted once, regardless of the number of components experienced. Counts will be compared between study groups.

Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
Percentage of participants with documented non-sustained ventricular tachycardia
Lasso di tempo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the insertable cardiac monitor (ICM) group with at least one adjudicated non-sustained ventricular tachycardia (NSVT) episode during each assessment window. Each participant is counted once per window, regardless of the number of episodes. The percentage is calculated as the number of participants with NSVT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of non-sustained ventricular tachycardia episodes per monitoring day
Lasso di tempo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Rate of all adjudicated non-sustained ventricular tachycardia (NSVT) episodes recorded by the insertable cardiac monitor (ICM). All qualifying episodes are counted, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of NSVT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. NSVT is classified according to the protocol definition.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Percentage of participants with documented sustained ventricular tachycardia
Lasso di tempo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the ICM group with at least one adjudicated sustained ventricular tachycardia (VT) episode during each assessment window. Each participant is counted once per window. The percentage is calculated as the number of participants with sustained VT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of documented sustained ventricular tachycardia episodes per monitoring day
Lasso di tempo: During the first 30 days and first 6 months after initiation of LUX monitoring

Rate of all adjudicated sustained VT episodes recorded by the ICM, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of sustained VT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. Results are expressed as sustained VT episodes per monitoring day.

During the first 30 days and first 6 months after initiation of LUX monitoring
Percentage of participants meeting the early composite PVC, NSVT, VT, or VF endpoin
Lasso di tempo: During the first 30 days and first 6 months of participant follow-up.

Percentage of participants meeting a composite endpoint comprising PVC, NSVT, sustained VT, or ventricular fibrillation (VF). A participant meets the endpoint if any component occurs and is counted once per assessment window. The percentage is calculated as the number of qualifying participants divided by the number in the analysis population, multiplied by 100, and compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Rate of events meeting the early composite PVC, NSVT, VT, or VF endpoint
Lasso di tempo: During the first 30 days and first 6 months of participant follow-up.

Rate of events meeting the composite endpoint comprising PVC, NSVT, sustained VT, or VF. Qualifying events will be counted according to protocol description and divided by time of follow-up. Results will be compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Mean premature ventricular contraction burden
Lasso di tempo: Throughout ICM monitoring, anticipated to last 36 months after implantation.

Mean premature ventricular contraction (PVC) burden recorded by the ICM in the ICM group. For each participant, daily device-recorded PVC burden, expressed as a percentage, will be averaged over the observation period. The participant-level averages will then be summarized as the group mean PVC burden

Throughout ICM monitoring, anticipated to last 36 months after implantation.
Change from baseline in EQ-5D-5L score
Lasso di tempo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Health status assessed using the EQ-5D-5L specific score. Changes from baseline will be calculated at 12, 24, and 36 months and compared between the ICM and standard-care groups to assess differences in change over time. There is also an visual analogue sclae with scores that ranges from 0 to 100, with higher scores indicating better perception of being healthy. Changes will be summarized using these scores

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from baseline in self-assessed NYHA class
Lasso di tempo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Functional status assessed using self-assessed New York Heart Association (NYHA) class. Changes from baseline will be determined at 12, 24, and 36 months and compared between the ICM and standard-care groups. Changes will be reported as NYHA class. Higher NYHA classes indicate greater functional limitation.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from the initial post-implant assessment in Florida Patient Acceptance Survey using the FPAS specific score
Lasso di tempo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Device acceptance assessed using the Florida Patient Acceptance Survey (FPAS) in the ICM group only. Changes from the initial post-implant assessment will be calculated at 12, 24, and 36 months to assess change over time. The score ranges from 0 to 100, with higher scores indicating better acceptance.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
NT-proBNP concentration
Lasso di tempo: Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

NT-proBNP concentration measured in blood samples and expressed in ng/L. Baseline concentrations will be evaluated as a predictor of cardiac arrhythmias. Follow-up concentrations will be collected only when measured during routine clinical care.

Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean daily coffee intake assessed using the study questionnaire
Lasso di tempo: At baseline, 12-, 24-, and 36 months

Participant-reported coffee intake assessed using the additional study questionnaire and expressed as cups per day. The mean number of cups consumed per day will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months
Mean weekly alcohol intake assessed using the study questionnaire
Lasso di tempo: At baseline, 12-, 24-, and 36 months

Participant-reported alcohol intake assessed using the additional study questionnaire and expressed as standard drinks per week. Mean weekly intake will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Reinoud E Knops, Prof, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 aprile 2026

Completamento primario (Stimato)

1 aprile 2030

Completamento dello studio (Stimato)

1 aprile 2031

Date di iscrizione allo studio

Primo inviato

20 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NL-010971

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi